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SUMMARY – This paper deliberates on the place and role of informed consent in everyday 
clinical laboratory practice. Taking into account international ethical guidelines such as the UNESCO 
Universal Declaration on Bioethics and Human Rights, the Declaration of Helsinki of the World 
Medical Association, and Croatian national laws and codes such as the Act on the Protection of 
 Patients’ Rights, the Act on Medical Biochemistry, the Code of Ethics of Medical Biochemists and 
Medical Deontology, the Act on Healthcare Services, and the Code of Ethics of the Croatian Cham-
ber of Healthcare Workers, an overview is given on the actual implementation of the aforementioned 
recommendations and regulations. A distinction between consent to a medical procedure and consent 
to enrolment in a research protocol is strongly stressed out. Special emphasis is placed on the role of 
specialists in laboratory medicine and masters of medical biochemistry in the process of obtaining 
informed consent. The design of an ‘informed consent interview’ is to be taken into consideration. 
Additional deliberation is needed on the option of ‘broad consent’. It is concluded that informed 
consent should represent an important and routine activity within Croatian clinical laboratories.
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Introduction
Informed consent is a current clinical reality, both 
in treatment and research. However, the clinical reality 
is constantly changing, particularly under the influence 
of new technologies. Therefore, the key issues from the 
period of the ‘birth of bioethics’ are nowadays a me-
mento of a romantic time when the ethical component 
of medicine managed to keep pace with its profession-
al-technical component. Informed consent, both as a 
theoretical value and as clinical practice, developed 
precisely from the vortex of time. It was rooted in the 
‘achievements’ of Nazi medicine, hovering for years 
over any research protocol as a silent admonition that 
‘it should never happen again’. The cradle of informed 
consent is the Nuremberg Code, which developed 
from the Nuremberg trials against Nazi physicians in 
1947. Its first point was that “the voluntary consent of 
the human subject is absolutely essential”1. Other 
points indicate that:
•	 the experiment should aim at positive results for 
society that cannot be procured in some other 
way;
•	 it should be based on previous knowledge (such 
as animal experiments) that justifies the experi-
ment;
•	 it should be designed to avoid unnecessary phys-
ical and mental suffering;
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•	 it should not be conducted when there is any 
reason to believe that it implies a risk of death or 
disability;
•	 it should put the risks in proportion to the ex-
pected benefits;
•	 procedures and facilities must be provided that 
adequately protect participants against the ex-
periment’s risks;
•	 researchers must be scientifically trained and 
qualified;
•	 participants must be free to quit the experiment 
at any point when they feel physically or men-
tally distressed; and
•	 researchers should stop the experiment at any 
point when they observe that continuation 
would be dangerous1.
The concept of informed consent first appeared in 
conducting research, which is a logical sequence. One 
might even call it ‘a burdened legacy’. In clinical me-
dicine (in terms of treatment, not trial), informed 
 consent has long been reserved only for the most con-
troversial interventions and procedures that have been 
considered ‘ethically exotic’2, balancing thereby be-
tween centuries of paternalism (‘physician-father’ 
knows best) and a shy entrance of the patient’s rights 
through the back door of medicine. Today, however, 
“decision-making and participation in decision-mak-
ing process about one’s own health is recognized as the 
patient’s human right”3.
The definition of informed consent evolved over 
time “from the narrow focus on the physician’s or re-
searcher’s obligation to disclose information about the 
quality of a patient’s or subject’s understanding of in-
formation and his right to authorize or refuse a bio-
medical intervention”4. This refers to an authorized 
action by the physician/researcher towards the patient/
subject. The concept is quite simple, “the physician 
cannot treat the patient before he/she presents him/
her with the basic information about the treatment 
and proposes an alternative procedure. The patient 
then decides what treatment he/she wishes to be ap-
plied to him/her, or if he/she wants for any treatment 
to be applied at all”3. What needs to be pointed out is 
that the “right to refuse the proposed medical proce-
dures is only the flip side of the right to giving consent 
and together they form a unity”, which emphasizes the 
patient’s/subject’s position of an ‘autonomous agent’3.
Informed consent is derived from two (bio)ethical 
principles, i.e. the traditional (hippocratic) principle of 
beneficence and the contemporary principle of auton-
omy5. Acting as the denominator of the two, at first 
glance conflicting principles, i.e. the physician’s obliga-
tion to make the care for the patient his top priority 
and the patient’s right to express his/her own will even 
though it may be contrary to the physician’s advice5, 
informed consent has importantly changed (i.e. it is 
continuously changing) the relationship between phy-
sicians and patients. This opens up space for practical 
application of informed consent, i.e. “it roots the con-
sent, that is, it gives the right to the protection of au-
tonomous choice”, ranging from individual patients to 
participants of scientific research6. In accordance with 
the principle of autonomy (voluntas aegroti suprema 
lex), every patient has the right to make independent 
decisions about his/her health and disease, about ac-
ceptance or refusal of the medical interventions pro-
posed, even about his/her stay in a medical institution, 
etc., assuming that he/she is capable of independent 
decision-making5. However, it is necessary to point out 
the difference between:
•	 general autonomy – institutional guidelines and 
protocols (i.e. social rules of consent) which de-
fine the legal and institutionally valid consent 
for all potential patients or subjects in a scien-
tific research; and
•	 personal autonomy – autonomous and informed 
authorization to conduct a medical intervention 
or participation in a study related to each indi-
vidual (which is expressed through the autono-
my of consent/choice, i.e. the right of approve/
refuse and/or the right to choose)5.
Precisely, the clinical laboratory services are located 
at the very crossroads of these two ‘subtypes’ of autono-
my. That is why healthcare professionals (as well as pa-
tients) often find themselves in a confusing situation 
where they are simply not sure whether it is necessary to 
request an informed consent for a particular procedure, 
or if it can be derived from institutional protocols which 
this procedure is subject to. So, do we even require an 
informed consent in the laboratory? If so, what kind? 
Specialized or conclusive? Written or oral? Who ‘gives’ 
and who ‘receives’ it? What does it mean to ‘give’ or ‘re-
ceive’ consent for a laboratory diagnostic test?
International (Bio)ethical Guidelines
In the medical-ethical-legal sense, informed con-
sent is in the clinical laboratory field directly or indi-
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rectly regulated by a number of international guide-
lines, as well as national laws and regulations. If we 
understand ethics as “a spotlight that illuminates the 
empirics”7, then the UNESCO Universal Declaration 
on Bioethics and Human Rights, and in particular the 
Declaration of Helsinki of the World Medical Asso-
ciation (WMA) constitute the starting point for dis-
cussion on these issues. They represent a kind of super-
structure, or supra-national medical-ethical-legal con-
structs, which serve as a foothold for derivation of na-
tional laws regulating the field of biomedicine and 
healthcare, and by-laws such as codes of individual 
professional chambers. When analyzing these docu-
ments, the notion should always be kept in mind that 
a consent or refusal of consent to a diagnostic or thera-
peutic procedure should not be equated with agreeing 
to participate in research.
The Universal Declaration on Bioethics and Hu-
man Rights was adopted by the 33rd General Confer-
ence of UNESCO in 2005. This Declaration “address-
es ethical issues related to medicine, life sciences and 
associated technologies as applied to human beings, 
taking into account their social, legal and environmen-
tal dimensions (...). Human dignity, human rights and 
fundamental freedoms are to be fully respected (…). 
The interests and welfare of the individual should have 
priority over the sole interest of science or the society 
(…)”8. One of the aims of this Declaration is “to rec-
ognize the importance of freedom of scientific research 
and the benefits derived from scientific and techno-
logical developments, while stressing the need for such 
research and developments to occur within the frame-
work of ethical principles set out in this Declaration 
and to respect human dignity, human rights and fun-
damental freedoms”8. The issue of informed consent is 
discussed in Articles 6 and 7.
The Declaration of Helsinki of the WMA was ad-
opted at the 18th general meeting in 1964 and supple-
mented several times. It represents “a statement of 
ethical principles for medical research involving hu-
man subjects, including research on identifiable hu-
man material and data”9. The Declaration is addressed 
primarily at physicians, but the WMA “encourages 
others who are involved in medical research involving 
human subjects to adopt these principles”9. Some of 
the Declaration’s General Principles referring to the 
topic are: “Medical research is subject to ethical stan-
dards that promote and ensure respect for all human 
subjects and protect their health and rights (…). It is 
the duty of physicians who are involved in medical re-
search to protect the life, health, dignity, integrity, right 
to self-determination, privacy, and confidentiality of 
personal information of research subjects. The respon-
sibility for the protection of research subjects must al-
ways rest with the physician or other healthcare pro-
fessionals and never with the research subjects, even 
though they have given consent”9.
Croatian Normative Framework
The Act on the Protection of Patients’ Rights 
(APPR) was adopted in 2004 and revised in 2008. This 
Act “defines the rights of patients when using health-
care, as well as the way to protect and promote those 
rights. The patient, in terms of this Act, shall mean any 
person, sick or healthy, who requests or who is under-
going certain measures or services for the purpose of 
preserving and improving health, preventing illness, 
treatment or medical care and rehabilitation”10. This 
Act guarantees to every individual, as the patient, “the 
general and equal right to quality and continuous 
healthcare, appropriate to his/her state of health, in ac-
cordance with the generally accepted professional 
standards and ethical principles, in the best interest of 
the patient, with respect to his/her personal views”10. 
The principles of humanity and accessibility are re-
spected in the provision of healthcare services. The ba-
sic rights that this Act regulates are the following: the 
right to co-decide (which includes an exception to the 
right to co-decide, the right to information, the right 
to refuse receipt of the information, the right to accept 
or refuse a medical procedure or treatment, and the 
right to protection of the patient who is unable to con-
sent), the right to confidentiality, privacy, and access to 
medical records, the right to maintenance of personal 
contacts, the right to arbitrary abandonment of health-
care institutions, as well as damage compensation. It 
also regulates the implementation of interventions in 
the human genome. The right to the protection of par-
ticipants in scientific research is especially empha-
sized10. Informed consent is regulated by Articles 6 
through 21.
The Act on Medical Biochemistry (AMB) was ad-
opted in 2003 and revised in 2008. It regulates the 
principles, organization, and carrying out of activities 
in the field of medical biochemistry. It relies on “con-
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stant efforts to maintain and raise the quality of medi-
cal and biochemical services in the interest of the 
health of the patient; the respect for the patients’ rights, 
the promotion of a dignified, responsible and profes-
sional conduct of a Master of Medical Biochemistry; 
and the adherence to the rules of the profession and 
the Code of Ethics of Medical Biochemists and Med-
ical Deontology”11.
The Code of Ethics of Medical Biochemists and 
Medical Deontology (CEMBMD) was adopted in 
2009 at the third session of the Chamber. The Code 
emphasizes that it is “a medical biochemist’s honorable 
duty to devote his/her profession to the health and 
well-being of man. A medical biochemist shall show a 
high degree of humanity and provide all available lab-
oratory services equally to all regardless of particulari-
ties such as age, sex, race, nationality, religion or politi-
cal belief, economic or social status and personal rela-
tionship with the user, thereby respecting human 
rights and dignity of the person. Abiding by the prin-
ciples of the Code, a medical biochemist shall observe, 
maintain and improve the moral and professional level 
of medical biochemistry”12. It is important to point out 
that, regarding research, the Code builds on the Dec-
laration of Helsinki, to which it directly refers (Article 
18 of the Code)12.
The Act on Healthcare Services was adopted in 
1987 and revised in 2009. It refers to the services pro-
vided by sanitary engineers, healthcare related radio-
logical-technological services, occupational therapy, 
and medical-laboratory services. Services of medical-
laboratory diagnostics are most commonly performed 
in a team whose head is the appropriate specialist in 
laboratory medicine or master of medical biochemis-
try. The Act defines the standard of education, the 
need for further training, the conditions for carrying 
out activities, and the duties and responsibilities of 
healthcare professionals. Particular emphasis is placed 
on the duty of carrying out services by applying the 
best professional knowledge, respecting the principles 
of medical ethics and the Code of Ethics of the Croa-
tian Chamber of Healthcare Workers, the duty to re-
spect the rights of patients, and the obligation to keep 
a professional secret13.
The Code of Ethics of the Croatian Chamber of 
Healthcare Workers (Code of Ethics and Deontology 
of Sanitary Engineering, Healthcare Radiological and 
Technological Services, Occupational Therapy, and 
Medical-Laboratory Services) was adopted in 2012. It 
contains a system of values and rules of professional 
conduct of healthcare workers, who are obliged to ad-
here to in their professional work. Among other things, 
the Code prohibits discrimination and emphasizes re-
spect for the rights and dignity of every person, pro-
vides an honorable, competent, responsible and quality 
service, and protects the patient’s or user’s information 
from other persons, the employer, and the wider com-
munity about the healthcare procedure and/or service 
being performed. It also describes the relationship 
with other healthcare workers and the profession, and 
emphasizes the respect of competences. Particular at-
tention is paid to participation in research and publi-
cation of scientific papers14.
Informed Consent in Croatian Clinical 
Laboratory Practice
The question that directly arises in practice seems 
at first glance to be a very logical one: do we need to 
conduct an ‘informed consent interview’5 every time 
when a patient comes to draw blood? Is the physician’s 
referral, which the patient brings to the laboratory, a 
form of consent to the laboratory procedure12? A com-
parison and interpretation of international and nation-
al medical-ethical-legal guidelines can be found in 
Table 1. When analyzing the displayed normative 
framework, it can be concluded that specialists in labo-
ratory medicine and masters of medical biochemistry, 
as well as bachelors of medical laboratory diagnostics 
and medical laboratory technicians should be involved 
in the process of informed consent, given that this is 
not merely the signing of such a form, but a concrete 
and important everyday clinical and, obviously, labora-
tory practice. The following considerations and pro-
posals are designed while keeping in mind the current 
Croatian clinical reality, but considering the approach 
to the problem through international ethical guide-
lines.
All the abovementioned healthcare professionals 
are invited to safeguard and promote the right of pa-
tients/health service users/research subjects to confi-
dentiality and privacy. They also participate in the pro-
tection of personal medical data15. Since clinical labo-
ratory services deal with the analysis of biological ma-
terial (blood, urine, cells, tissue, cerebrospinal fluid, 
etc.), attention should be paid to the protection of 
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personal data. Specifically, the protection of medical 
personal data occupies a special place within the 
framework of the protection of personal data. Data on 
a person’s health status are very important and they 
belong to specific data that require strict standards, 
which regulate the access to such information with re-
gard to authorized persons and under certain condi-
tions16. It should be borne in mind under what condi-
tions and in what circumstances may the data on the 
health status of a person be available, and how the pa-
tient’s personal data can be protected to the best extent 
possible16.
The right to information is a prerequisite for the 
right to accept/refuse medical treatment or research. 
In order to counteract the debate about what informa-
tion should be provided, to whom, how, and who 
should provide it17, the creation of information materi-
als has been proposed, which would be available to pa-
tients/subjects in their preparation for a particular 
medical procedure/research involving laboratory tests. 
In this way, the patient will have the opportunity in an 
environment unburdened by time restrictions to study 
all the relevant information and be autonomously able 
to ask questions. This contributes to the promotion of 
the ‘health literacy’18 of patients/users/subjects who 
thus become more active participants in the process of 
giving-receiving informed consent.
If a patient comes to the laboratory with a physi-
cian’s referral for laboratory testing, having such a re-
ferral is treated as written consent12, and an ‘informed 
consent interview’ need not be further implemented. 
If a patient-client comes to the laboratory without a 
referral (i.e. at their own request, with the obligation of 
a financial compensation for the service), it is in ac-
cordance with the principles of ‘good laboratory prac-
tice’ to conduct an interview of informed consent. It is 
the obligation of all healthcare professionals to enable 
access to medical information, but it is within the ob-
ligation of specialists in laboratory medicine and mas-
ters of medical biochemistry to deliver such informa-
tion to the patient. In this case, it is also suggested to 
create sets of informed consent forms for particular 
sets of tests.
Genetic testing is a separate topic, and because of 
the specificity of test subjects (individuals, relatives 
and descendants can be seen as a group patient), it re-
quires a more detailed approach, but it is clear that 
there must be a previously obtained patient’s/user’s in-
formed consent19. So, some laboratory procedures can-
not be categorized as a ‘conclusive agreement’, but for 
them the patient must give a separate consent17. Re-
solving the issues of the (non)possession of informed 
consent to a genetic testing (but it could also be ap-
plicable to other testing) before arrival of the patient/
user to the laboratory would greatly facilitate daily 
work. Following the model of Mayo Medical Labora-
tories, it is recommended to define the list of tests that 
would require from patients/clients to have written 
informed consent already on file, obtained from their 
physician20.
Testing for human immunodeficiency virus, hepa-
titis, etc., may pose a problem if the patient/user with 
full capacity of consent does not want to receive infor-
mation on the outcome of the test result. Then the 
medical biochemist acts in accordance with Articles 
14 and 15 of the APPR because they refer to cases 
where the patient/user must be aware of the nature of 
their disease, so as not to endanger the health of oth-
ers. A notification is then given to the ‘surrogate’, and 
if there is a referral pursuant to Article 10 of the Code 
of Ethics, then the patient’s/user’s physician, who has 
recommended the testing, will be immediately noti-
fied10,12.
Finally, for each medical procedure, except for cases 
of medical emergencies, it is necessary to obtain in-
formed consent in writing (e.g., a referral). Giving an 
oral or combined consent in laboratories is usually not 
the case, except for people with disabilities who have 
requested the testing themselves. Also, in accordance 
with the principles of medical law, a patient/user can 
always refuse to submit to a diagnostic testing, unless 
he/she thereby threatens the health of others8,10,12. In 
that case, bachelors of medical laboratory diagnostics 
and medical laboratory technicians are obligated to im-
mediately notify the head of the team (specialist in lab-
oratory medicine or master of medical biochemistry)13.
Since medical research in a laboratory is carried out 
using identifiable human material or data, such as re-
search on material or data contained in Biobanks or 
similar repositories, the medical biochemist and medi-
cal laboratory technician (MLT) must seek a written 
informed consent for the collection, storage and/or 
reuse for epidemiological, demographic or other scien-
tific purposes9,12. The possibility of an oral and com-
bined consent, i.e. a lack of necessity for consent in the 
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situations where consent would be impossible or im-
practicable to obtain, such as in retrospective-prospec-
tive research (e.g., use of existing samples on which it 
is proposed to implement a new analysis), it might be 
done only after consideration and approval of the local 
ethics committee9,10,12.
It should be noted that the Code of Ethics, as the 
fundamental document of the professional law of 
medical biochemists, protects the profession and the 
individual very elegantly with the following formula-
tion of Article 22 in an attempt to prevent confusion 
in practice: “If a medical biochemist is not sure wheth-
er a certain situation is in accordance with this Code, 
he/she shall consult with the Board of Medical Ethics 
and the deontology of the Medical Chamber”12. A 
proposal to define a laboratory protocol of conducting 
an ‘informed consent interview’ is shown in Table 2.
Conclusion
As initially stated, the clinical reality is constantly 
changing, so let us take a glimpse into the future of 
informed consent in laboratory practice. In the United 
States, a revision was conducted in 2011 with the aim 
to enhance the Federal Policy for the Protection of 
Human Subjects or the Common Rule. In 2015, a No-
tice of Proposed Rule Making was issued in the Fed-
eral Register and nearly 2200 public comments were 
received. They reveal differing opinions about the 
changes proposed. Final revisions to the Common 
Rule were issued by the U.S. Department of Health 
and Human Services (HHS) and fifteen other Federal 
Departments and Agencies in January 2017. The pur-
pose was to implement better human research subject 
protection, but also to help (re)build public trust. The 
majority of changes will go into effect in  January 
201821-25. Some of the major changes being proposed 
are those relating to informed consent, such as new 
consent elements, changes to waiver criteria and docu-
mentation, and a ‘broad consent’ (i.e. consent for fu-
ture) option for unspecified future use of identifiable 
data/bisopecimens26-28.
In the revised Common Rule, broad consent is de-
fined as “seeking prospective consent to unspecified 
research”26. It represents an optional/alternative con-
sent process for the storage, maintenance, and second-
ary usage of identifiable biospecimens for future, still 
unspecified research. Before ‘activating’ the obtained 
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of research that may be conducted with the data/bio-
specimens,  and determine whether proposed future 
secondary biospecimen use falls within the scope of 
the identified types of  research26-28.
The latter recommendation, should it be consid-
ered and adopted in Croatian laboratories, would 
greatly facilitate the implementation of studies on hu-
man material, as much as it may seem complicated at 
first glance to seek broad consent27. In any case, either 
through classical informed consent interview and/or 
approval by a local ethics committee (when needed), or 
by seeking broad consent, this would resolve one of the 
key issues encountered in everyday laboratory practice: 
should the rest of the blood remaining in the test tube 
after the completion of the required analysis be dis-
posed of or can it be reused?
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Sažetak
INFORMIRANI PRISTANAK U HRVATSKOJ KLINIČKOJ LABORATORIJSKOJ PRAKSI  
– AKTUALNA PITANJA I BUDUĆE PERSPEKTIVE
I. Sorta-Bilajac Turina i V. Šupak Smolčić
Rad se bavi mjestom i ulogom informiranog pristanka u svakodnevnoj kliničkoj laboratorijskoj praksi. Uzimajući u obzir 
međunarodne etičke smjernice kao što su UNESCO-va Opća deklaracija o bioetici i ljudskim pravima, Helsinška deklara cija 
Svjetskog medicinskog udruženja te hrvatske nacionalne zakone i kodekse kao što su Zakon o zaštiti prava pacijenata, Zakon 
o medicinsko-biokemijskoj djelatnosti, Etički kodeks medicinskih biokemičara i medicinske deontologije, Zakon o djelatno-
stima u zdravstvu te Etički kodeks Hrvatske komore zdravstvenih radnika daje se pregled aktualne primjene navedenih 
preporuka i propisa. Naglašava se potreba za razlikovanjem pristanka na medicinski postupak od pristanka na sudjelovanje u 
istraživanju. Ističe se uloga specijalista laboratorijske medicine i magistara medicinske biokemije u procesu informiranog 
pristanka. Sugerira se kreiranje ‘intervjua informiranog pristanka’. Potrebna je daljnja rasprava o mogućnosti uvođenja ‘opće 
suglasnosti’. Zaključno, informirani pristanak trebao bi predstavljati značajnu i uobičajenu aktivnost u kliničkim laboratori-
jima u Hrvatskoj.
Ključne riječi: Obaviješteni pristanak; Biokemija; Kliničke laboratorijske službe; Hrvatska
